Lotus Pharmaceutical Co. Ltd v. GlaxoSmithKline LLC
1:16-cv-00377
Overview
Parties
Defendant
Glaxo Group Limited NPE (University / Research)
Represented By
0 Attorneys ListedGlaxoSmithKline LLC NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
Lotus Pharmaceutical Co. Ltd Operating Company
Represented By
3 Attorneys ListedHeyman Enerio Gattuso & Hirzel LLP
300 Delaware Avenue, Suite 200, Wilmington, DE 19801
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,637,512 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| π¬π§ United Kingdom | GB 0217493 A | United Kingdom Counterpart | View Official Patent → |
| π¬π§ United Kingdom | GB 0217492 A | United Kingdom Counterpart | View Official Patent → |
| π¬π§ United Kingdom | GB 0313801 A | United Kingdom Counterpart | View Official Patent → |
| πΊπΈ United States | US 2005003279 | US Continuation / Sibling | View Official Patent → |
Alembic Pharmaceuticals Limited v. GlaxoSmithKline LLC
Patents Involved
There are 2 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8637512
Formulations and method of treatment
|
Filed: 2003-12-02
Issued: 2014-01-28
|
Active (2.1 yrs remaining)
+1863d PTA
Expires: 2029-01-07
|
|
|
US9144547
Oral dosage form for controlled drug release
|
Filed: 2010-12-13
Issued: 2015-09-29
|
Expired (Term Ended)
Expires: 2023-09-22
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+1863 days) / Cellect Scrutiny β Over 1863 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).